Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2014-11-24 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2014
Regulatory Filings Classification · 90% confidence The document is titled "Company Announcement" and details a specific operational update: the initiation of a Phase II clinical study for the drug daratumumab in smoldering multiple myeloma. It includes details about the study design, the drug, and the collaboration partner. This type of announcement, focusing on clinical trial progress and operational milestones rather than comprehensive financial results (like 10-K or IR) or management changes (MANG), is best classified as a general Regulatory Filing or Company Announcement that doesn't fit a more specific category. Since it is a specific operational update and not a general regulatory filing fallback (RNS), and it is not a financial report, earnings release, or management discussion, the most appropriate category among the provided options for a specific, non-financial, non-governance operational update is often the general Regulatory Filing (RNS) if no better fit exists. However, given the context of biotech/pharma announcements, this is a standard press release detailing R&D progress. Since there is no specific code for 'Clinical Trial Update' or 'Press Release', and it is not a financial report (ER, IR, 10-K), nor a management/governance item, it falls under the general regulatory/company announcement category, RNS, as it is a formal communication to the market about a significant development.
2014-11-24 English
Director's Dealing 2014
Director's Dealing Classification · 99% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and explicitly states that it is reporting transactions made by leading employees and their close associates regarding Genmab shares, as required by securities trading law (§ 28a). The details provided include the name of the executive (Jan van de Winkel), his role (CEO), the transaction type (Purchase/exercise of warrants), date, and number of shares. This content directly corresponds to the definition of Director's Dealing (insider trades by executives).
2014-11-12 Danish
Director's Dealing 2014
Director's Dealing Classification · 99% confidence The document is titled "Report Pursuant to Section 28a of the Danish Securities Trading Act" and explicitly states it is making public information on "transactions by managerial employees and their related parties involving Genmab shares." It details a specific purchase transaction by the CEO, including the date, number of shares, and value. This content directly matches the definition of Director's Dealing (insider trades by executives). The corresponding code is DIRS.
2014-11-12 English
Share Issue/Capital Change 2014
Share Issue/Capital Change Classification · 98% confidence The document is titled "Company Announcement" and details a specific corporate action: an increase in share capital resulting from the exercise of employee warrants. It specifies the number of shares, the subscription prices, the total proceeds, and the resulting change in the CEO's personal holding and the company's total share capital. This action directly relates to changes in the company's capital structure and share issuance. This aligns precisely with the definition for 'Share Issue/Capital Change' (SHA). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS) because it concerns a specific, defined capital event.
2014-11-12 English
Share Issue/Capital Change 2014
Share Issue/Capital Change Classification · 98% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and details a specific corporate action: an increase in share capital ('forhøjer selskabets aktiekapital') resulting from the exercise of employee warrants. It specifies the number of new shares, the subscription prices, the total proceeds, and the impact on the CEO's holdings and the total share capital. This action directly relates to changes in the company's capital structure and share issuance. This aligns precisely with the definition for 'Share Issue/Capital Change' (SHA). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific capital event.
2014-11-12 Danish
Regulatory Filings 2014
Regulatory Filings
2014-11-10 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.